Precigen reports first quarter 2022 financial results and business updates

– fast track designation received for prgn-3006 ultracar-t®, an important milestone for patients with relapsed or refractory acute myeloid leukemia, a rapidly progressing disease with limited treatment option s –  – phase 1b expansion arm initiated for prgn-3006 ultracar-t ® at dose level 3 with lymphodepletion   – –  dosing initiated in patients at dose level 3 via intravenous infusion with lymphodepletion in the prgn-3005 ultracar-t® phase 1 study – –  phase 2 study initiated for prgn-2012 adenoverse ™ immunotherapy as an adjuvant treatment in patients with recurrent respiratory papillomatosis – – cash, cash equivalents, short-term and long-term investments totaled $142.1 million as of march 31, 2022 – – company to host a pipeline update call in the coming months  – germantown, md. , may 9, 2022 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2022 financial results and business updates.
PGEN Ratings Summary
PGEN Quant Ranking